NTLA vs VRTX
NTLA and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $1.72B | $130.87B |
| P/E (TTM) | — | 30.1 |
| P/B | — | 6.46 |
| P/S | 25.4x | 10.9x |
| Revenue | — | $12.59B(TTM) |
| Revenue growth (YoY) | 16.9% | 8.9% |
| Net income | — | $4.41B(TTM) |
| Earnings growth (YoY) | 20.5% | 838.1% |
| EPS, diluted | — | $17.17(TTM) |
| EBIT margin | -651.7% | 34.8% |
| ROE | -56.7% | 19.5% |
| ROIC | — | 25.0% |
| 1y total return | -1.1% | +33.5% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: NTLA vs VRTX
| Metric | NTLA | VRTX |
|---|---|---|
| End value | $4.9K | $62.9K |
| Total return | -50.9% | +528.6% |
| CAGR | -6.7% | +19.5% |
| Volatility | 78.2% | 32.7% |
| Sharpe | 0.25 | 0.58 |
| Sortino | 0.37 | 0.86 |
| Max drawdown | -96.5% | -41.6% |
Based on 2600 common trading days, 2016-05-16 → 2026-09-17 · risk-free 4.12% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)